Sponsored by NASA s Office of Advanced Concepts and Technology (OACT), the Commercial Protein Crystal Growth (CPCG) middeck payload on STS-51 is developed by the Center for Macromolecular Crystallography (CMC), a NASA Center for the Commercial Development of Space based at the University of Alabama in Birmingham. This payload will use the CMC-developed Protein Crystallization Facility (PCF) to process interferon alfa-2b(TradeMark) provided by the Schering Plough Research Institute. The PCF uses temperature as the controlling parameter for crystallization of the proteins. The STS-51 Flight, currently planned for launch in July 1993, will be the sixth flight of the PCF; the fifth flight took place on STS-57 as part of the SPACEHAB-01 payload complement in June 1993. The enclosed Mission Operation Report contains a brief description of the CPCG-03 activity on STS-51. Inquiries may be directed to the OACT Flight Programs Division.
Commercial Protein Crystal Growth (CPCG-03) on STS-51
1993
13 pages
Report
Keine Angabe
Englisch
Protein crystal growth in microgravity: Status and commercial implications
American Institute of Physics | 1999
|Protein Crystal Growth in Microgravity: Status and Commercial Implications
British Library Conference Proceedings | 1999
|Solution Crystal Growth: Commercial Opportunities
British Library Conference Proceedings | 1998
|Commercial crystal growth in space
Tema Archiv | 1991
|